111, Inc. (YI) is a Medical - Pharmaceuticals company in the Healthcare sector, currently trading at $6.81. It has a SharesGrow Score of 27/100, indicating a weak investment profile with 1 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of YI = $32.89 (+383% from the current price, the stock appears undervalued).
Valuation: YI trades at a trailing Price-to-Earnings (P/E) of -5.4 (S&P 500 average ~25).
Financials: revenue is $14.4B, +5.2%/yr average growth. Net income is $65M (loss), growing at +41.9%/yr. Net profit margin is -0.4% (negative). Gross margin is 5.8% (+0.8 pp trend).
Balance sheet: total debt is $257M with negative equity of -$643M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 1.13 (adequate). Debt-to-assets is 9.2%. Total assets: $2.8B.
SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 83/100 (Pass), Past 0/100 (Fail), Health 25/100 (Fail), Moat 27/100 (Fail), Future ?/100 (Fail), Income 10/100 (Fail).
